Your browser is no longer supported. Please, upgrade your browser.
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-1.28 Insider Own0.60% Shs Outstand160.39M Perf Week-0.38%
Market Cap3.35B Forward P/E36.11 EPS next Y0.58 Insider Trans-35.94% Shs Float156.23M Perf Month7.63%
Income-201.00M PEG- EPS next Q0.64 Inst Own96.80% Short Float4.07% Perf Quarter-8.59%
Sales1.07B P/S3.12 EPS this Y-0.90% Inst Trans-0.77% Short Ratio3.95 Perf Half Y-5.91%
Book/sh6.80 P/B3.07 EPS next Y11.37% ROA-11.30% Target Price24.73 Perf Year-38.20%
Cash/sh3.66 P/C5.70 EPS next 5Y29.50% ROE-18.10% 52W Range17.11 - 37.75 Perf YTD-29.28%
Dividend- P/FCF240.82 EPS past 5Y-56.50% ROI-7.70% 52W High-44.72% Beta1.78
Dividend %- Quick Ratio2.40 Sales past 5Y20.40% Gross Margin83.00% 52W Low21.98% ATR0.73
Employees2300 Current Ratio2.70 Sales Q/Q2.60% Oper. Margin-15.40% RSI (14)53.53 Volatility3.38% 3.63%
OptionableYes Debt/Eq0.26 EPS Q/Q-51.70% Profit Margin-18.70% Rel Volume0.51 Prev Close21.25
ShortableYes LT Debt/Eq0.26 EarningsJan 22 BMO Payout- Avg Volume1.61M Price20.87
Recom2.70 SMA200.33% SMA505.84% SMA200-14.02% Volume824,709 Change-1.79%
Sep-05-19Upgrade Morgan Stanley Underweight → Equal-Weight $30 → $20
Jul-15-19Upgrade Goldman Sell → Neutral
May-31-19Initiated H.C. Wainwright Neutral
May-01-19Downgrade Citigroup Buy → Neutral
Dec-19-18Downgrade Goldman Neutral → Sell
Dec-14-18Initiated Wolfe Research Underperform
Dec-13-18Downgrade Credit Suisse Outperform → Underperform
Nov-05-18Initiated Piper Jaffray Neutral $40
Aug-07-18Initiated Stifel Hold $15 → $45
Jun-21-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18Initiated B. Riley FBR, Inc. Buy $60
May-16-18Upgrade Citigroup Neutral → Buy
May-11-18Initiated BofA/Merrill Buy $56
Apr-02-18Downgrade Evercore ISI Outperform → In-line
Feb-22-18Downgrade Jefferies Buy → Hold
Oct-16-17Downgrade Barclays Overweight → Equal Weight $66 → $50
Jun-13-17Downgrade Leerink Partners Outperform → Mkt Perform
Oct-21-16Upgrade JP Morgan Neutral → Overweight
Oct-21-16Reiterated Leerink Partners Outperform $57 → $70
Oct-21-16Reiterated Jefferies Buy $62 → $70
Dec-13-19 08:33AM  Momenta Pharmaceuticals (MNTA) Catches Eye: Stock Jumps 7.1% Zacks
Dec-12-19 09:36AM  Amgen's Osteoporosis Drug Evenity Gets Approval in Europe Zacks
09:10AM  Proteostasis Therapeutics (PTI) in Focus: Stock Moves 7.3% Higher Zacks
Dec-11-19 12:12PM  FDA told Alkermes to stop publishing Vivitrol ad MarketWatch
12:03PM  UPDATE 1-FDA issues warning letter to Alkermes over opioid addiction treatment ad Reuters
11:25AM  FDA issues warning letter to Alkermes over opioid addiction treatment ad Reuters
Dec-10-19 09:26AM  TG Therapeutics' Shares Soar on Positive Early-Stage Data Zacks
Dec-09-19 04:31PM  Regeneron Reports Initial Data for Multiple Myeloma Drug Zacks
04:03PM  bluebird Reports Positive Top-Line Data on Myeloma Drug Zacks
Dec-08-19 07:52AM  Should You Be Pleased About The CEO Pay At Alkermes plc's (NASDAQ:ALKS) Simply Wall St.
Dec-06-19 09:26AM  Sage Therapeutics' Depression Drug Fails in Study, Stock Down Zacks
09:17AM  Hedge Funds Are Warming Up To Alkermes Plc (ALKS) Insider Monkey
Dec-05-19 10:02AM  Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug Zacks
09:07AM  Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon Zacks
Dec-04-19 10:10AM  AstraZeneca Sells Schizophrenia Drug Rights in US and Canada Zacks
09:29AM  Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 6.4% in Session Zacks
Dec-03-19 03:18PM  Epizyme Announces FDA Committee Review of Tazemetostat NDA Zacks
09:16AM  Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU Zacks
08:29AM  Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1% Zacks
Nov-29-19 09:26AM  Global Blood (GBT) in Focus: Stock Moves 5.2% Higher Zacks
09:13AM  BioDelivery's Belbuca Sales & Symproic Addition Encouraging Zacks
Nov-27-19 08:52AM  ChemoCentryx Up on Encouraging Rare Disease Candidate Data Zacks
Nov-26-19 08:36AM  Myovant (MYOV) Catches Eye: Stock Jumps 6.7% Zacks
08:24AM  Intercept's (ICPT) NDA for NASH Drug Gets Priority Review Zacks
Nov-25-19 09:18AM  Alexion Gets Approval for Label Expansion of Soliris in Japan Zacks
07:00AM  Alkermes Completes Acquisition of Rodin Therapeutics PR Newswire
Nov-22-19 09:45AM  Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy Zacks
09:31AM  Alkermes (ALKS) Up 3% Since Last Earnings Report: Can It Continue? Zacks
Nov-21-19 10:24AM  Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi Zacks
09:54AM  Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria Zacks
09:01AM  Alnylam (ALNY) Catches Eye: Stock Jumps 10.5% Zacks
Nov-20-19 09:41AM  Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher Zacks
09:31AM  Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More Zacks
09:30AM  Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug Zacks
Nov-19-19 09:36AM  Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline Zacks
09:26AM  Protalix Finalizes Accelerated Approval Pathway for PRX-102 Zacks
07:00AM  Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder PR Newswire
Nov-18-19 05:25PM  Celgene's Revlimid-Rituximab Combo Gets Positive CHMP Opinion Zacks
08:22AM  Struggling drugmaker Alkermes buys Boston biotech American City Business Journals
07:30AM  Alkermes to acquire Rodin Therapeutics for up to $950 million MarketWatch
07:00AM  Alkermes to Acquire Rodin Therapeutics PR Newswire
Nov-15-19 10:02AM  VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints Zacks +5.37%
08:57AM  Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal Zacks
Nov-14-19 03:08PM  Biogen shares fall 3% MarketWatch
10:20AM  BioDelivery (BDSI) Stock Up on Q3 Earnings Beat & Raised View Zacks
Nov-13-19 09:23AM  Top Ranked Momentum Stocks to Buy for November 13th Zacks
09:05AM  Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss Zacks
08:00AM  IVERIC bio (ISEE) Q3 Loss Narrows Y/Y, Zimura Advancing Well Zacks
Nov-12-19 04:01PM  Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences PR Newswire
09:52AM  Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat Zacks
07:00AM  Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY PR Newswire
Nov-08-19 02:33PM  Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates Zacks
10:08AM  Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis Zacks
10:00AM  Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus Zacks
09:32AM  Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up Zacks
08:56AM  Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat Zacks
08:14AM  The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut Benzinga
07:00AM  Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting PR Newswire
Nov-07-19 02:30PM  7 Stocks the Vanguard Health Care Fund Keeps Buying GuruFocus.com
11:53AM  Biotech Stock On The Radar: Alkermes At A Crossroads Benzinga
11:08AM  Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales Zacks
11:05AM  Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates Zacks
10:47AM  Zacks.com featured highlights include: Qualys, Fortinet, Zumiez, Commvault Systems and Alkermes Zacks
Nov-06-19 08:13AM  Check 5 Best Liquid Stocks for Impressive Returns Zacks
Nov-04-19 07:00AM  Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting PR Newswire
Nov-03-19 10:51AM  The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight Benzinga
Oct-30-19 10:34AM  Biogens Alzheimers Drug Could Be a Winner. One Analyst Recommends the Bet. Barrons.com
08:03AM  UPDATE 2-Small relief for Biogen in MS drug approval Reuters
07:40AM  Biogen's and Alkermes' Vumerity gets FDA approval for MS; Biogen's stock surges MarketWatch
07:30AM  Biogen and Alkermes Announce FDA Approval of VUMERITY (diroximel fumarate) for Multiple Sclerosis GlobeNewswire
Oct-29-19 11:10AM  Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View Zacks
09:00AM  All You Need to Know About Alkermes (ALKS) Rating Upgrade to Strong Buy Zacks
Oct-24-19 10:41PM  Edited Transcript of ALKS earnings conference call or presentation 23-Oct-19 12:00pm GMT Thomson Reuters StreetEvents
11:09AM  Is Alkermes Plc (ALKS) Going To Burn These Hedge Funds ? Insider Monkey
10:06AM  Alkermes' (ALKS) Earnings and Sales Beat Estimates in Q3 Zacks
07:17AM  How Many Alkermes plc (NASDAQ:ALKS) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Oct-23-19 02:29PM  Drugmaker Alkermes cuts 160 jobs in effort to lower expenses American City Business Journals
08:25AM  Alkermes (ALKS) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM  Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring PR Newswire
Oct-22-19 11:32AM  Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More Zacks
Oct-21-19 07:00AM  Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230 PR Newswire
Oct-16-19 04:01PM  Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results PR Newswire
Oct-08-19 08:33AM  Biogen Strengthens MS & SMA Portfolio as Competition Lurks Zacks
Oct-07-19 07:00AM  Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress PR Newswire
Sep-26-19 04:01PM  Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-24-19 11:27AM  Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy Zacks
Sep-18-19 10:00AM  Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry? Simply Wall St.
Sep-13-19 07:15PM  Alkermes Plc (ALKS) Director and CEO, Alkermes plc Richard F Pops Sold $2.3 million of Shares GuruFocus.com
07:00AM  Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D. PR Newswire
Sep-06-19 06:15PM  Alkermes Plc (ALKS) Director and CEO, Alkermes plc Richard F Pops Sold $2 million of Shares GuruFocus.com
Aug-24-19 09:31AM  Why Is Alkermes (ALKS) Down 3.9% Since Last Earnings Report? Zacks
Aug-19-19 02:19PM  An Intrinsic Calculation For Alkermes plc (NASDAQ:ALKS) Suggests It's 49% Undervalued Simply Wall St.
Aug-02-19 10:04AM  Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down Zacks
Jul-31-19 11:36AM  Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates Zacks
Jul-30-19 03:05PM  Biogen Hedged Its Bet and Won Big Motley Fool +5.99%
07:30AM  Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis PR Newswire
07:30AM  Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis GlobeNewswire
Jul-29-19 12:30PM  Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute PR Newswire +6.32%
11:57AM  Edited Transcript of ALKS earnings conference call or presentation 25-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Jul-26-19 01:45PM  Alkermes Bounces Back -- but Not Enough Motley Fool
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. It also has a clinical research collaboration with Fred Hutchinson Cancer Research Center for ALKS 4230, Alkermes' immuno-oncology drug candidate to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
POPS RICHARD FDirector and CEO, Alkermes plcNov 14Option Exercise9.21100,000921,000816,433Nov 15 04:08 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 14Sale19.50100,0001,950,000716,433Nov 15 04:08 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 13Option Exercise9.2120,000184,200205,122Nov 15 04:07 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 13Sale19.7020,000394,056185,122Nov 15 04:07 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Option Exercise9.2130,205278,188746,638Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Sale19.7330,205595,827716,433Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 07Option Exercise9.2169,795642,812786,228Nov 08 04:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 07Sale19.8169,7951,382,618716,433Nov 08 04:06 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 06Option Exercise9.2120,000184,200205,122Nov 08 04:04 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 06Sale19.7620,000395,116185,122Nov 08 04:04 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 19Option Exercise9.21100,000921,000816,433Sep 23 06:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 19Sale21.54100,0002,153,550716,433Sep 23 06:16 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSSep 13Option Exercise11.7420,000234,80058,256Sep 17 07:06 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 12Option Exercise9.21100,000921,000816,433Sep 13 05:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 12Sale22.68100,0002,268,220716,433Sep 13 05:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 05Option Exercise9.21100,000921,000816,433Sep 06 05:01 PM
POPS RICHARD FDirector and CEO, Alkermes plcSep 05Sale20.18100,0002,017,830716,433Sep 06 05:01 PM
MITCHELL PAUL JDirectorJul 01Option Exercise8.987,00062,8607,000Jul 02 06:24 PM
Hopkinson Craig C.SVP, Med Dev/Med Affairs, CMOJun 07Option Exercise0.001,25007,245Jun 10 05:13 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 23Option Exercise8.5550,000427,500766,433May 24 08:09 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 23Sale24.2250,0001,211,150716,433May 24 08:09 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 22Option Exercise8.5520,000171,000205,122May 23 05:50 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 22Sale24.9320,000498,532185,122May 23 05:50 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 16Option Exercise8.5560,000513,000776,433May 24 08:09 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 16Sale25.4260,0001,525,278716,433May 24 08:09 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 09Option Exercise8.557,00059,85053,923May 13 05:54 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 09Sale26.895,373144,49848,550May 13 05:54 PM
Robinson James A. Jr.President & COO,Alkermes, Inc.Apr 04Option Exercise0.006,25006,250Apr 05 05:10 PM
MITCHELL PAUL JDirectorApr 01Option Exercise8.981,0008,9801,000Apr 02 07:00 PM
MITCHELL PAUL JDirectorApr 01Sale36.641,00036,6400Apr 02 07:00 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 14Option Exercise8.5525,000213,750210,122Mar 14 06:53 PM
Wysenski NancyDirectorMar 14Buy33.0644514,7124,302Mar 18 05:05 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 14Sale33.0525,000826,373185,122Mar 14 06:53 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 13Option Exercise8.5515,829135,338732,262Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 13Sale33.5115,829530,485716,433Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 12Option Exercise8.5544,171377,662760,604Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 12Sale33.2444,1711,468,447716,433Mar 14 06:38 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 07Option Exercise8.5520,000171,000205,122Mar 07 06:20 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 07Sale32.0720,000641,362185,122Mar 07 06:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 05Option Exercise8.5550,000427,500766,433Mar 07 06:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 05Sale33.6350,0001,681,740716,433Mar 07 06:16 PM
MITCHELL PAUL JDirectorMar 01Option Exercise8.981,0008,9801,000Mar 04 05:13 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 01Option Exercise0.0017,5000724,203Mar 04 05:53 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 01Option Exercise0.004,5000186,445Mar 04 05:50 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 01Option Exercise0.002,250047,585Mar 04 05:45 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 01Option Exercise0.004,500051,044Mar 04 05:35 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 01Option Exercise0.002,250031,064Mar 04 05:27 PM
MITCHELL PAUL JDirectorMar 01Sale33.481,00033,4800Mar 04 05:13 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 26Option Exercise0.0010,0000710,590Feb 27 05:20 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 26Option Exercise0.002,6250182,717Feb 27 05:18 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 26Option Exercise0.001,100045,659Feb 27 05:15 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 26Option Exercise0.002,625047,316Feb 27 05:12 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 26Option Exercise0.001,100029,138Feb 27 05:08 PM
Wysenski NancyDirectorFeb 21Buy33.093,857127,6283,857Mar 18 05:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 17Option Exercise0.008,7500703,163Feb 19 07:12 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 17Option Exercise0.003,0000180,965Feb 19 07:05 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 17Option Exercise0.002,500045,285Feb 19 06:56 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 17Option Exercise0.003,000045,566Feb 19 06:53 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 17Option Exercise0.002,500028,767Feb 19 06:51 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 16Option Exercise0.0018,1250699,753Feb 19 07:12 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 16Option Exercise0.003,3750179,074Feb 19 07:05 PM
Hopkinson Craig C.SVP, Med Dev/Med Affairs, CMOFeb 16Option Exercise0.003,37507,078Feb 19 07:03 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 16Option Exercise0.003,375043,893Feb 19 06:56 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 16Option Exercise0.003,375043,664Feb 19 06:53 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 16Option Exercise0.002,375027,092Feb 19 06:51 PM
MITCHELL PAUL JDirectorFeb 01Option Exercise8.981,0008,9801,000Feb 01 05:01 PM
MITCHELL PAUL JDirectorFeb 01Sale32.731,00032,7300Feb 01 05:01 PM
MITCHELL PAUL JDirectorJan 04Option Exercise8.981,0008,9801,000Jan 04 06:01 PM
MITCHELL PAUL JDirectorJan 04Sale30.001,00030,0000Jan 04 06:01 PM